Method of post-surgical treatment of cerebral tumour
SUBSTANCE: for the purpose of post-surgical treatment of cerebral tumours, memantine is prescribed in a dose of 10 mg daily for 5-7 days before radiation therapy, and in a dose of 20 mg during radiation therapy 4-6 hours before the radiation session. On completing the course of radiation therapy, memantine is prescribed in patients aged up to 60 years old in a dose of 10 mg for 2-3 months daily, in patients aged 60 and older in a dose of 20 mg for 5-6 months daily.
EFFECT: method enables providing the higher patients' quality of life with a view to cancellation of glucocorticoids, ensuring higher clinical effectiveness ensured by an increase of the medullary substance to radiation.
The invention relates to medicine and can be used in the treatment of patients with brain tumor.
Malignant brain tumors are the most frequently diagnosed cancer of the Central nervous system. Standard treatment for these tumors is surgical removal of the tumor followed by adjuvant radiotherapy in standard mode fractionation of the dose of irradiation to a total dose of 60 Gy. Local recurrence after treatment occurs, usually 12-14 months. It is believed that the reason for such an early relapse is the lack of technical capacity total removal of the tumor due to the fact that it has no clear boundaries with the surrounding intact the substance of the brain or its localization in the area of vital centers of the nervous system, limiting surgical activity. No less important cause of relapse is high radioresistance of residual tumor, irradiation in the dose of 60 Gy leads to only sublethal damage to its forming cells. The increase in the number of fatal injuries is possible only by increasing the total dose of radiation more than 60 Gy or a single dose of irradiation. But the use of such aggressive treatment inevitably leads the children to the damage of the brain, entering the target irradiation, which in itself can cause death of the patient. In order to reduce the negative impact of irradiation on the substance of the brain are used glucocorticoids, however, causing a number of serious side effects, such treatment may exacerbate the already precarious condition of the patient. In some cases, such as patients with diabetes, the use of glucocorticoids is impossible, which casts doubt on the feasibility of adjuvant radiation therapy in these patients and dooms them to a premature death.
There is a method of treatment of malignant brain tumors, when during adjuvant radiation therapy the patient is prescribed the introduction of corticosteroids to reduce brain edema resulting from radiation damage to the elements of the microvasculature of the brain (Cancer Res Treat. -2006. - V.128. - P.7-22. Shaw EG, Robbins, M.E.).
The disadvantage of this method are profound metabolic disturbances in the body of the patient in response to the introduction of glucocorticoids, which significantly impairs the physical condition of patients, the cause of sleeplessness, depression and in some cases is the cause of interruption of the course of radiation therapy. All this negatively affects the comfort and life expectancy of such patients. Given the initial method of treatment cannot be applied in patients with diabetes, since the introduction of glucocorticoids lead to decompensation of diabetes mellitus, and instead of reducing the damaging effects of irradiation on the brain caused the opposite effect - the degree of radiation damage of blood vessels in patients with diabetes mellitus on the background of the introduction of glucocorticoids increased, which caused the development of radiation necrosis and death of patients.
Closest to the claimed is a method of treatment of malignant brain tumors (RF Patent No. 2143893, IPC AC 31/17, publ. 2000), including a course of radiation and drug therapy involving before and during adjuvant radiotherapy for patients with malignant brain tumor assign a blocker of the calcium receptor. Chemotherapy is drug microsociety.
The disadvantages of this method is that the use of a blocker of the calcium receptor is limited in elderly patients with concomitant cardiac pathology, and, as shown in statistics, older patients among those who need adjuvant radiation therapy in connection with a brain tumor the majority. Blocker calcium receptor acts mainly at the level of the vascular wall brain, while radiation damage occur in the vascular wall and the cellular elements and the article is ome matter of the brain. Restricted use of the drug in violation of cerebral circulation, and among those patients who received surgical removal of the tumor, enough. The drug is terminated with the end of radiation therapy that is unreasonable from the point of view of the duration of radiation disease variability that occurs in the tumor, and the substance of the brain in response to irradiation.
The objective of the proposed method is to eliminate the above disadvantages, the efficiency of the treatment, reducing the radioresistance of residual tumor by increasing its oxygenation, reducing the damaging effects of radiation on the intact the substance of the brain by inactivation processes of peroxide oxidation, leading to oxidative stress, normalization of coagulation homeostasis in the brain, improving the efficiency of adjuvant radiation therapy by increasing pay and total doses, reducing timing of radiation therapy.
To solve the task during the course of radiation and drug therapy proposed as drug therapy to prescribe oral administration of memantine. 5-7 days before the beginning of radiation therapy prescribed for administration of memantine 10 mg daily during radiation therapy administered 20 mg for 4-6 hours before the session exposed the deposits. After radiation therapy patients under the age of 60 years shall receive of memantine 10 mg in 2-3 months daily, patients aged 60 years or more, appointed reception of memantine 20 mg for 5-6 months on a daily basis.
The occurrence of radiation damage of the microvasculature and cellular elements of the brain lead to greater degree of edema and hypoxia in the radiation zone, activation of anaerobic glycolysis followed by excessive release of glutamate and the violation of its reuptake. As a mediator excitation, glutamate causes prolonged stimulation of the cells, resulting in excessive entrance of calcium ions with subsequent release of proteases, which leads to accumulation in the cell of hydroperoxides, the development of oxidative stress and its destruction.
The above processes lead to spasm of cerebral vessels, platelet aggregation and the appearance of coagulation changes of hemostasis, which leads to increased hypoxia in the tumor and reduces the effectiveness of the treatment.
The purpose of memantine in patients whose planned adjuvant radiation therapy leads to normalization of blood-brain barrier permeability by suppressing the activity of P21, p38/MARK and reduce the degree of hypoxia of the brain, has an antioxidant EF is known, which leads to the rejection of the use of glucocorticoids, a more rapid recovery of brain functions are lost during surgical intervention, allows a shorter time to start exposure. On balance radioprotective properties of this drug in regard to the substance of the brain the opportunity to use more aggressive methods of radiation therapy, increasing as a single dose and total dose of radiation. Considering the fact that the processes of radiation-induced and causing oxidative stress, continue to operate after the termination of adjuvant radiation therapy, justified the admission of memantine at the stage of monitoring patients after completion of treatment. Moreover, it is essential that you should take into account the degree and depth of radiation damage, and these indicators are more pronounced in elderly patients. In this regard, the possibility to individually determine the dosage and timing of reception of memantine.
The implementation of the method is demonstrated on specific clinical examples.
Patient B., 50 years, performed surgical removal of a brain tumor. Histological examination showed that the tumor is a glioblastoma (malignant glioma 4 tbsp. PLN). In the postoperative period the patient about what was algal to complain of General weakness, right-sided hemiparesis, he noted cognitive disorders, dementia.
2 weeks after surgery scheduled memantine at a dose of 10 mg per day and cancelled dexamethasone. The patient's condition improved significantly, within 7 days after the start of treatment, memantine was appointed radiation therapy mode hypofractionation dose, which continued without interruption until the SOD=68 Gr.
During the entire course of radiation therapy the patient received memantine in daily doses of 20 mg, his condition remained stable, almost regressed symptoms of hemiparesis and dementia, recovered memory.
After completion of radiotherapy, the patient continued taking the memantine 10 mg per day. His health has remained satisfactory.
6 months after completion of radiation therapy on MRI in a patient not detected foci of damage to the substance of the brain and relapse.
Patient K., 63, uninstalled anaplastic astrocytomas (malignant glioma 3 tbsp. PLN). brain.
After the appointment of memantine in daily doses of 10 mg for 5 days, the patient is assigned to adjuvant radiation therapy, which was held in the classic mode fractionation of the radiation dose to 64 Gy. Throughout the course of therapy the patient received daily 20 mg of memantine. After C is the conclusion of adjuvant radiation therapy reception of memantine at a dose of 20 mg daily was continued and discontinued only after 6 months.
During the entire course of radiation therapy and 6-month follow-up period for the patients he needed no further introduction glucocorticoids, his condition remained satisfactory.
The proposed method of treatment was applied to 25 patients with different morphological forms of malignant brain tumors. Daily take of memantine in the recommended dosage before, during and after adjuvant radiation therapy was allowed in all cases, significantly improve the quality of life of patients due to the failure of the introduction of glucocorticoids and, as a consequence, the lack of patients the occurrence of deep metabolic disorders. In the course of adjuvant radiation therapy had no grounds to terminate the exposure. Reception of memantine resulted in improved cognitive brain function, memory, allowed patients to care for themselves without assistance.
The conduct of adjuvant radiation therapy in patients receiving antagonist extrasynaptic glutamate receptors of memantine on the proposed scheme can significantly increase the tolerance of the elements of the substance of the brain to irradiation by reducing oxidative stress, improve time and total dose of radiation that will have a positive impact on the effectiveness of the treatment I n the patients with malignant brain tumors in different age groups.
The method of treatment of malignant brain tumors in the postoperative period, including a course of radiation and drug therapy, characterized in that the quality of drug therapy prescribed oral administration of memantine 10 mg daily for 5-7 days prior to the start of radiation therapy during radiation therapy prescribed for administration of memantine 20 mg for 4-6 hours before the session, after the end of radiation therapy for patients under the age of 60 years shall receive of memantine 10 mg in 2-3 months daily, patients aged 60 years or more is prescribed reception of memantine 20 mg for 5-6 months daily.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, namely to an agent with an antidyslipidemic and analgesic effect. The method for preparing the phytocomplex with the antidyslipidemic and analgesic effect, involving: a) grinding peeled bergamot fruit to prepare an undegraded mixture, b) introducing pectinolytic enzymes into the mixture; c) reducing pulp content; d) inactivating the above enzymes added at the stage b), to prepare a degraded mixture; e) performing ultrafiltration of the degraded mixture through membranes isolating the substances having a molecular weight of over 30,000 Da, to prepare a transparent solution; f) introducing the transparent solution on a polyphenol absorption column; g) washing the polyphenol absorption column with water and increasing pH to prepare an aqueous polyphenol fraction; h) transmitting the aqueous polyphenol fraction to cationic resin to recover the phytocomplex in an aqueous phase; i) drying the phytocomplex in the aqueous phase. The phytocomplex in the aqueous phase with the antidyslipidemic and analgesic effect. The phytocomplex with the antidyslipidemic and analgesic effect. A pharmaceutical composition with the antidyslipidemic effect containing the phytocomplex, and pharmaceutically acceptable additives. A pharmaceutical composition with the analgesic effect containing the phytocomplex, and pharmaceutically acceptable additives.
EFFECT: phytocomplex described above possesses the evident antidyslipidemic and analgesic effect.
SUBSTANCE: method involves preliminary intraperitoneal single administration of 5% aqueous alloxan in a dose of 15 mg/kg of body weight into a rat's body on an empty stomach. That is followed by administering afobazol under conditions of oxidative stress after observing the rat's blood glucose gain at least twice. Afobazol is administered subcutaneously in a dose of 10 mg/kg of body weight once a day for 30 days with underlying administration of L-arginine in a dose of 10 mg/kg of body weight or with underlying NG-nitroarginine methyl ester (L-NAME)-inhibitor of NOS-3 enzyme in a dose of 25 mg/kg of animal's weight.
EFFECT: method enables correcting the oxidative stress and NO-producing endothelial dysfunction accompanying vascular complications of diabetes mellitus.
1 dwg, 6 tbl, 1 ex
SUBSTANCE: invention concerns an antioxidant representing the amino acid glycine immobilised on the detonation-synthesised nanodiamond particles of 2-10 nm in size.
EFFECT: higher efficacy.
4 cl, 5 dwg, 7 tbl, 3 ex
SUBSTANCE: improving the functional result of a low resection of rectum in the patient suffering from rectum cancer is ensured by prescribing the drug preparation Laviocard+ 1 capsule 2 times a day with food for the pre-operative radiation course, one day before the operation and for 30 postoperative days to the extent of the low resection of rectum.
EFFECT: invention enables reducing a rate and degree of defecation and continence dysfunctions following the low resection of rectum and the radiation therapy.
1 tbl, 1 ex
SUBSTANCE: invention relates to compound for formula (1) , antioxidant, containing formula (1) compound or its salt as active ingredient, and to application of formula (1) compound or its salt for oxidant manufacturing. Invention also relates to formula (2) compound, which is intermediate for obtaining formula (1) compound.
EFFECT: formula compound, demonstrating antioxidant properties.
4 cl, 1 tbl, 13 ex
SUBSTANCE: invention refers to pharmaceutical industry, particularly to a method for increasing the radioresistance in mice. The method for increasing the radioresistance in mice consisting in the fact that 20-30 min before a radiation exposure, parsley juice diluted with normal saline is introduced intramuscularly.
EFFECT: method increases the radioresistance in mice effectively.
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to medicine. A pharmaceutical formulation for the treating diseases associated with endothelial dysfunction contains an active ingredient presented by a methyl pyridine derivative - 1.0-6.0 wt %; purine - 10.0-80.0 wt % and additive agents - the rest. The active substance is presented by compounds of a group: 3 -(N,N-dimethyl carbamoyloxy)-2-ethyl-6-methylpyridinium succinate, 3-methylpyridinium succinate, 2-ethyl-6-methyl-3-hydroxypyridinium hydrochloride, 6-trichloromethyl-2-chloropyridine (nitrapyrin), 2-ethyl-6-methyl-3-hydroxypyridine succinate. Purine is presented by inosine, adenosine, hypoxanthine. The pharmaceutical formulation may be presented in the form of injections, lyophilisate, solid capsules, tablets and suppositories.
EFFECT: formulation according to the invention provides creating the stable drug dosage form which considerably exceeds the existing analogues in pharmacodynamics activity on the endothelial dysfunction and toxicological properties.
4 cl, 4 tbl, 9 ex
SUBSTANCE: invention relates to diastereomers of isobornyl compounds of the structural formula (I), where R1=H and isobornyl fragments have the configuration (1S, 2R, 4R, 1'S, 2'R, 4'R) and (1R, 2S, 4S, 1'R, 2'S, 4'S), where R1=CH3 and isobornyl fragments have the configuration (1S, 2R, 4R, 1'R, 2'S, 4'S) or the isobornyl fragments have the configuration (1S, 2R, 4R, 1'S, 2'R, 4'R) and (1R, 2S, 4S, 1'R, 2'S, 4'S).
EFFECT: high antioxidant activity.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to cosmetology. What is presented is using a cell culture prepared of one or more homogenous cell lines originated from cambium Panax ginseng, or extract thereof when preparing an anti-aging cosmetic composition.
EFFECT: invention provides the effective agent for preventing or suppressing the aging ensured by the antioxidant effect of the natural materials being the ingredients of the above composition.
7 cl, 7 dwg, 20 tbl, 12 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a polyphenol derivative formulation and is used in cosmetics, nutrition science and therapy. The polyphenol derivative formulation possessing antioxidant and antiradical activity and having an effect on carbonyl stress. A method for preparing the formulation. The cosmetic formulation possessing antioxidant and antiradical activity and having an effect on carbonyl stress. Using the formulation in nutrition science. The formulation to be used as a therapeutic agent possessing antioxidant and antiradical activity and having an effect on carbonyl stress. The pharmaceutical formulation possessing antioxidant and antiradical activity and having an effect on carbonyl stress.
EFFECT: formulation has an effect on carbonyl stress.
23 cl, 11 dwg, 5 ex
FIELD: food industry.
SUBSTANCE: invention relates to compositions for maintenance or increase of growth and cognitive development of a foetus, baby or child; the compositions contain one or more complex lipid(s) where the complex lipid(s) include(s) at least approximately 0.1% of gangliosides of dry substance weight. Additionally, the invention relates to application of the complex lipid(s) for production of the said compositions wherein the said lipids include at least approximately 0.1% of gangliosides of dry substance weight. Additionally, the invention relates to methods for maintenance or increase of growth and cognitive development of a foetus, baby or child; the methods involve the said compositions administration to a foetus, baby or child in need thereof. Additionally, the invention envisages providing a pregnant woman with the said compositions and informing her that the composition will maintain or increase growth or maintain or increase cognitive development of the foetus.
EFFECT: invention ensures expansion of the range of means for maintenance or increase of growth and cognitive development of a foetus, baby or child.
52 cl, 6 dwg, 5 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: in formula R1 is H or (1-6C alkyl); R2 represents NRbRc, (1-4C)alkyl, (1-4C)fluoroalkyl, CF3, (1-4C)hydroxyalkyl, -(1-4Calkyl)hetAr1, -(1-4Calkyl)NH2, -(1-4C alkyl)NH(1-4Calkyl), -(1-4Calkyl)N(1-4Calkyl)2, hetAr2, hetCyc1, hetCyc2, phenyl substituted where applicable by NHSO2(1-4Calkyl) or (3-6C)cycloalkyl, substituted where applicable by (1-4C alkyl), CN, OH, OMe, NH2, NHMe, N(CH3)2, F, CF3, CO2(1-4C alkyl), CO2H; C(=O)NReRf or C(=O)ORg; Rb is H or (1-6C alkyl); Rc represents H, (1-4C)alkyl, (1-4C)hydroxyalkyl, hetAr3 or phenyl, wherein the above phenyl is substituted where applicable by one or more substitutes independently from halogen, CN, CF3 and -O(1-4C alkyl); Re represents H or (1-4C)alkyl; Rf represents H, (1-4C)alkyl or (3-6C)cycloalkyl; Rg represents H or (1-6C)alkyl; X is absent or represents -CH2-, -CH2CH2-, -CH2O- or -CH2NRd; Rd represents H or (1-4C alkyl); R3 represents H or (1-4C alkyl); and n is equal to 0-6. The radical values NRbRc, Y, hetAr1, hetAr2, hetAr3, hetCyc1, hetCyc2, NReRf, R4 are specified in the patent claim. The invention also refers to a pharmaceutical composition containing the above compounds, to a method of treating Trk kinase mediated diseases and conditions, such as pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection, osteolytic disease, and to a method of preparing the above compounds.
EFFECT: invention refers to new derivatives of pyrazolo[1,5-a]pyrimidines possessing an inhibitory activity on tropomyosin-related kinases (Trk).
42 cl, 1 tbl, 105 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to organic chemistry and medicine and concerns new compounds of formula , a based pharmaceutical composition containing the above compounds, and a method of treating a condition or a disorder mediated by the kinurenine-3-monooxygenase activity.
EFFECT: invention extends the range of agents active in relation to kinurenine-3-monooxygenase.
17 cl, 2 tbl, 15 ex
SUBSTANCE: invention refers to medicine, namely neurology, and is applicable for treating damaged remitting multiple sclerosis. That is ensured by introducing autologous regulatory T-cells of CD4+CD25+Foxp3+ grown ex vivo at 4.5-5.5 mln cells per 1 kg of a patient's body weight in the remitting multiple sclerosis remission stage.
EFFECT: using the given method provides increasing of CD4+CD25+Foxp3+ regulatory T-cells by 2 times and more and maintaining a normal level which enables prolonging the remission stage up to 12 months.
13 dwg, 3 ex, 5 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely to neurology, and concerns treating infectious diseases accompanied by neurotoxic disorders. That is ensured by administering a pharmaceutical composition containing an activated-potentiated form of human gamma-interferon (IFN-γ) antibodies and an activated-potentiated form of brain-specific protein S-100 antibodies.
EFFECT: drug preparation provides effective treatment of the above pathology ensured by the synergetic action of the ingredients of the composition.
9 cl, 4 dwg, 1 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to biopharmacology and represents a composition, a method and a set, which include a single-chain antibody scFv and a penetration-enhancing substance, selected from amino acid sequences, with a peptide being bound with a protective group with N-terminus, and the penetration-enhancing substance facilitates delivery of large macromolecules (i.e. larger than 10 kDa) through intercellular contacts.
EFFECT: group of inventions provides delivery of therapeutic antigen-binding polypeptides into CNS by intranasal introduction for treatment of neurological disorders.
8 cl, 14 dwg, 8 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a compound having a structure according to formula I:
compositions containing the compounds of the above formula applicable to stimulate neurogenesis and/or inhibition of neuron degeneration.
EFFECT: invention may be used in treating diseases and conditions characterised by neuron loss and lower neurogenesis, including Alzheimer's disease, stroke, traumatic brain injury, traumatic nerve injury and depression.
8 cl, 2 tbl, 2 ex, 1 dwg
SUBSTANCE: invention relates to a method of enhancing cognitive function in an animal or human being. Said method includes administering a compound which is selected from a group consisting of: steviol, isosteviol, and a mixture of steviol and isosteviol in a cognitive function enhancing amount. The invention also relates to a composition and nutraceutic agent containing one of said compounds or a mixture thereof.
EFFECT: invention improves learning capacity, intelligence and memory.
8 cl, 10 dwg, 6 tbl, 14 ex
SUBSTANCE: group of inventions relates to medicine, namely to neurology, and deals with treatment of attention deficit disorder. For this purpose introduced is a pharmaceutical composition, containing potentiated form of antibodies to brain-specific protein S-100 and as an additional enhancing component - an activated-potentiated form of antibodies to endothelial NO-synthase.
EFFECT: method provides efficient treatment of attention deficit disorder due to synergic action of active components of the pharmaceutical composition.
9 cl, 4 tbl, 1 dwg, 2 ex
SUBSTANCE: invention relates to the field of biotechnology and medicine. Claimed is a method of treating Alzheimer's disease, associated with low production of IL-10. The method includes increase of IL-10 level in an individual by introduction of efficient quantity of IL-10 or a molecule, increasing IL-10 production. Beta-amyloid can be one version of such a molecule. The claimed group of inventions can be used in medicine.
EFFECT: claimed is application of IL-10 for obtaining medication for treatment or prevention of Alzheimer's disease.
7 cl, 6 dwg, 9 tbl, 3 ex
SUBSTANCE: what is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours.
EFFECT: method provides safety of ultrafast opioid detoxification and prolongs the remission in the given category of patients.